Shiyu Capital of Shenzhen closed its second China life science PE fund with $473 million in capital. The fund, called Danqing Fund II, will invest in pharma/biotech, healthcare, IVD and medical services companies. The Danqing funds aim to participate in the “historic opportunity” of transforming China’s pharmaceutical industry. The company’s first fund, launched in 2016, raised $164 million. Both funds are RMB denominated. Shiyu Capital, also known as Shenzhen Shiyu Investment Management, was established in 2014.
Source: China Biotoday
